Related Experiment Video
Updated: Feb 10, 2026

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
Published on: August 11, 2017
Orphan Drugs and Their Impact on Pharmaceutical Development
Misty M Attwood1, Mathias Rask-Andersen2, Helgi B Schiöth1
1Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, Sweden.
Abstract:
High levels of productivity, with an increasing number of approvals for new molecular entities (NMEs) by the FDA during the past decade, have coincided with the emergence of innovative drugs for treatments of rare diseases that have utilized the FDA orphan drug program. Since 2000, NMEs with orphan designation encompass a significant portion of approved drugs and constitute about 80% of the approved drugs that have established novel human genome-encoded products in recent years. Biological approvals are also expanding, with 40% of the approved biological agents having orphan designation. This trend illustrates a pivot within the pharmaceutical industry: from research programs that focus on canonical blockbuster indications and targets, towards the establishment of new treatments for rare and difficult to treat diseases.
More Related Videos
07:23Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
Published on: October 20, 2023
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Related Concept Videos
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Pharmaceutical Equivalents
Drug Control Governance: Regulatory Bodies and Their Impact
Impact of Groups on Groups
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence